drugset / Trial / NCT02909166

Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.

NCT02909166

Phase 3 Unknown 70 enrolled Mika Lehto
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of the study is to find out whether aliskiren reduces atrial fibrillation burden measured with a pacemaker device

Timeline

Start
2012-01
Primary completion
2016-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aliskiren Small molecule

Indications